FDA approves AstraZeneca Etcamah after ctDNA detects breast cancer resistance before scans
FDA approves Etcamah after an ESR1 mutation is detected in blood before breast cancer progresses on scans, creating a first for ctDNA-guided treatment.
Pharma & Biotech